Over the past year, Altria Group has climbed from an overlooked "dying tobacco giant" to one of the best performing titles in the US consumer sector. The stock is up more than 20% YTD, yet the market still can't clearly answer one question: is this a temporary rebound from an oversold range, or the beginning of a true revaluation of the entire company? Behind this uncertainty is a fundamental transformation that is not visible from simple numbers. Altria is no longer a pure cigarette company. The new oral nicotine pouches under the On! PLUS have just received federal approval and kicked off U.S. distribution, while the cigarette segment's underlying operating margin has reached a historic 63%, despite a 10% annual decline in volumes.

The question of whether Altria can achieve a price of around $100 in five years is not absurd. It's a mathematical problem with three variables: how fast earnings per share will grow, how the valuation multiple the market will willingly accept will change,…